MedTrace Logo

Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis

NCT05754996 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-09-02

No results posted yet for this study

Summary

This is a pilot study designed to evaluate the efficacy and safety of nifuroxazide in the treatment of hepatic encephalopathy in patients with grade II-III hepatic encephalopathy

Conditions

  • Hepatic Encephalopathy

Interventions

DRUG

Nifuroxazide

Nifuroxazide dosing : 200 mg capsule four times daily

DRUG

Lactulose

Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools

DRUG

Rifaximin 550Mg Tab

Rifaximin 550 MG twice daily

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Mennat Allah S. Emam · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-12
Primary Completion
2025-07-29
Completion
2025-07-29

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05754996 on ClinicalTrials.gov